Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations (2016 - 2025)

Seres Therapeutics' Cash from Operations history spans 11 years, with the latest figure at 2206000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 106.36% year-over-year to 2206000.0; the TTM value through Sep 2025 reached 23055000.0, up 85.34%, while the annual FY2024 figure was 148609000.0, 26.63% down from the prior year.
  • Cash from Operations for Q3 2025 was 2206000.0 at Seres Therapeutics, up from 13289000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 127742000.0 in Q3 2021 and bottomed at 76584000.0 in Q1 2023.
  • The 5-year median for Cash from Operations is 39695000.0 (2021), against an average of 24856000.0.
  • The largest YoY upside for Cash from Operations was 593.86% in 2021 against a maximum downside of 189.3% in 2021.
  • A 5-year view of Cash from Operations shows it stood at 51863000.0 in 2021, then decreased by 1.98% to 52892000.0 in 2022, then rose by 10.2% to 47499000.0 in 2023, then rose by 18.14% to 38882000.0 in 2024, then skyrocketed by 105.67% to 2206000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Cash from Operations are 2206000.0 (Q3 2025), 13289000.0 (Q2 2025), and 26910000.0 (Q1 2025).